Research graph
References from Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program. Local targets link to admitted publications; unresolved targets remain external evidence.
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology
10.1016/s1473-3099(21)00191-2 · 2021 · External reference
The geographic distribution of dimorphic mycoses in the United States for the modern era
10.1093/cid/ciac882 · 2023 · External reference
Surveillance for coccidioidomycosis, histoplasmosis, and blastomycosis—United States, 2019
2022 · External reference
Tolerability of long-term fluconazole therapy
10.1093/jac/dky501 · 2019 · External reference
Large-scale evaluation of in vitro amphotericin B, triazole, and echinocandin activity against coccidioides species from U.S. institutions
10.1128/aac.02634-16 · 2017 · External reference
Isavuconazole in the treatment of chronic forms of coccidioidomycosis
10.1093/cid/ciad146 · 2023 · External reference
Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis
10.1093/mmy/myy029 · 2019 · External reference
Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal nfections
10.3390/jof6040239 · 2020 · External reference
Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers
10.1128/aac.01623-22 · 2023 · External reference
APX001 and other Gwt1 inhibitor prodrugs are effective in experimental coccidioides immitis pneumonia
10.1128/aac.01715-18 · 2019 · External reference
Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits
10.1128/aac.01795-20 · 2021 · External reference
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants
10.1128/aac.01455-23 · 2024 · External reference
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a phase 2 trial
10.1093/jac/dkad256 · 2023 · External reference
Fosmanogepix for the treatment of invasive mold diseases caused by aspergillus species and rare molds: a phase 2, open-label study (AEGIS)
10.1093/cid/ciaf185 · 2025 · External reference
Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial
10.1128/aac.01419-22 · 2023 · External reference
